Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. PMID 11806796.
Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.CS1 maint: multiple names: authors list (link)
Zeitlinger M, Müller M (2003). "[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]". Wien Med Wochenschr (ภาษาเยอรมัน). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.
Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005). "[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]". Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku (ภาษาญี่ปุ่น) (123): 41–5. PMID 16541751.CS1 maint: multiple names: authors list (link)
เซอร, วาสแตต, งกฤษ, cerivastatin, อการค, baycol, lipobay, เป, นยาลดระด, บไขม, นในกระแสเล, อดกล, มสแตต, นท, ได, จากการส, งเคราะห, โดยม, อบ, งใช, เพ, อลดระด, บคอเลสเตอรอลในเล, อดและเพ, อป, องก, นการเก, ดโรคห, วใจและหลอดเล, อด, จจ, นเซอร, วาสสแตต, นถ, กถ, อล, ขส,. esxriwasaettin xngkvs Cerivastatin chuxkarkha Baycol Lipobay epnyaldradbikhmninkraaeseluxdklumsaettinthiidcakkarsngekhraah odymikhxbngichephuxldradbkhxelsetxrxlineluxdaelaephuxpxngknkarekidorkhhwicaelahlxdeluxd pccubnesxriwassaettinthukthuxlikhsiththikarphlitaelacdcahnayinshrthxemrikaodybristhyathimichux ebeyxr ex ci Bayer A G tngaetchwngthaythswrrs 1990 odyintladkhxngyaldikhmninkraaeseluxdchnidihminkhnann esxriwasaettinkhxngebeyxrnnthuxepnkhuaekhngsakhykhxngxaothwasaettin sungepnyaklumediywkncakbristhifesxr sungepnbristhyathiprasbkhwamsaercepnxyangmakinwngkartladya txmainpi kh s 2001 ebeyxr ex ci idykelikkarcahnayaelathxnesxriwasaettinxxkcaktladyathwolkdwykhwamsmkhric enuxngcakphbkarekidxakarkhangekhiyngthirunaerng khux karesiychiwitcakorkhklamenuxlayslay fatal rhabdomyolysis esxriwasaettinkhxmulthangkhlinikradbkhwamesiyngtxtharkinkhrrphAU Dchxngthangkarrbyakarrbprathanrhs ATCC10AA06 WHO kthmaysthanatamkthmaythukthxnxxkcaktladkhxmulephschclnsastrkhrungchiwitthangchiwphaph2 3 chwomngtwbngchichuxtamrabb IUPAC 3R 5S 6E 7 4 4 fluorophenyl 5 methoxymethyl 2 6 bis propan 2 yl pyridin 3 yl 3 5 dihydroxyhept 6 enoic acidelkhthaebiyn CAS145599 86 6 CAS PubChem CID446156IUPHAR BPS2950DrugBankDB00439 7ChemSpider393588 7UNIIAM91H2KS67KEGGD07661 7ChEBICHEBI 3558 7ChEMBLCHEMBL1477 7khxmulthangkayphaphaelaekhmisutrC 26H 34F N O 5mwltxoml459 55 g molaebbcalxng 3D JSmol Interactive imageSMILES O C O C C H O C C H O C C c1c nc c c1c2ccc F cc2 COC C C C C C CInChI InChI 1S C26H34FNO5 c1 15 2 25 21 11 10 19 29 12 20 30 13 23 31 32 24 17 6 8 18 27 9 7 17 22 14 33 5 26 28 25 16 3 4 h6 11 15 16 19 20 29 30H 12 14H2 1 5H3 H 31 32 b11 10 t19 20 m1 s1 7Key SEERZIQQUAZTOL ANMDKAQQSA N 7 7 7 what is this verify saranukrmephschkrrmkarsuksaaelaefarawngtidtamkarichyahlngkarwangtlad aekikhinrahwangkarsuksaaelaefarawngtidtamkarichyaesxriwasaettinhlngcakyaxxkwangcahnayinthxngtladaelw post marketing surveillance PMS phbraynganphupwycanwn 52 rayesiychiwitkhnaxyurahwangkarichesxriwasaettin odymisaehtuhlkmacakklamenuxlayslayaelaitwayechiybphln sungepnphlkrathbcakkarekidorkhklamenuxlayslaytxhnung 1 odykhwamesiyngtxkarekidkhwamphidpktidngklawcaephimmakyingkhuninklumphuthiichesxriwasaettinrwmkbyaldikhmnineluxdifebrt odyechphaaecmifobrsil Gemfibrozil chuxkarkha Lopid rwmipthungphuthiichesxriwasaettininkhnadsung 0 8 mg day dwy hlngcakphbrayngankarekidkhwamphidpktidngklaw 18 eduxn bristhebeyxr ex ci idphicarnaephimkhxhamichephimetimlngbnbrrcuphnthkhxngesxriwasaettin odyhamichesxriwasaettinrwmkbecmifobrsil 2 thngni emuxepriybethiybxubtikarnkarekidorkhklamenuxlayslayrahwangesxriwasaettinkbyasaettinchnidxun phbwa xubtikarnkarekidkhwamphidpktidngklawkhxngphuthiichesxriwasaettinsungkwaphuthiidrbsaettinchnidxunthung 16 80 etha 3 yingipkwann yngphbphupwythiekidorkhklamenuxlayslaythiimkxihekidkaresiychiwit nonfatal rhabdomyolysis rahwangkarichesxriwasaettinpraman 385 khn sungsungkwasaettinchnidxun 5 10 etha nxkcakniaelwesxriwasaettinyngsamarthehniywnaihekidxakarklamenuxxxnaerng myopathy sungkhwamrunaerngxakardngklawmikhwamsmphnthaebbaeprphntrngkbkhnadyathiphupwyidrb aetkarekidxubtikarndngklawnnthukepidephyxxkmaodyebeyxrphayhlngthibrisththukfxngrxngaelamikarepidephyexksarkhxngbrisththiekiywenuxngkbpraedndngklawaetimekhytiphimphchiaecngmakxn 4 duephim aekikhxaothwasaettin fluwasaettin olwasaettin prawasaettin orsuwasaettin simwasaettin emwasaettin phithawasaettinxangxing aekikh Furberg CD Pitt B Withdrawal of cerivastatin from the world market Curr Control Trials Cardiovasc Med 2001 2 205 207 PMID 11806796 Psaty BM Furberg CD Ray WA Weiss NS 2004 Potential for conflict of interest in the evaluation of suspected adverse drug reactions use of cerivastatin and risk of rhabdomyolysis JAMA 292 21 2622 31 doi 10 1001 jama 292 21 2622 PMID 15572720 CS1 maint multiple names authors list link Zeitlinger M Muller M 2003 Clinico pharmacologic explanation models of cerivastatin associated rhabdomyolysis Wien Med Wochenschr phasaeyxrmn 153 11 12 250 4 doi 10 1046 j 1563 258X 2003 03029 x PMID 12879633 Saito M Hirata Koizumi M Miyake S Hasegawa R 2005 Withdrawal of cerivastatin revealed a flaw of post marketing surveillance system in the United States Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku phasayipun 123 41 5 PMID 16541751 CS1 maint multiple names authors list link bthkhwamekiywkbephschkrrmaelayaniyngepnokhrng khunsamarthchwywikiphiediyidodyephimkhxmul duephimthi sthaniyxy ephschkrrmekhathungcak https th wikipedia org w index php title esxriwasaettin amp oldid 9238551, wikipedia, วิกิ หนังสือ, หนังสือ, ห้องสมุด,